Compare Invesco Solar ETF (TAN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs Tango Therapeutics Inc. — how do they compare? Invesco Solar ETF trades at $42.4 (market cap $881.52M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 4.3× Invesco Solar ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 35 Days and Tango Therapeutics Inc. for 0 Days on average.
| TAN | TNGX | |
|---|---|---|
Market Cap | $881.52M | $3.75B |
Volume | 3,915,267 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $32.90 |
52-Week Low | $42.64 | $7.50 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $44.38, up 2.07% today but facing bearish technical signals with sell signals outweighing buys 11-8. The solar ETF shows mixed sentiment amid sector volatility, with recent news highlighting both policy tailwinds from U.S. tariffs and headwinds from high borrowing costs impacting project financing.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. While geopolitical shifts favor renewable energy adoption, TAN's high expense ratio and historical underperformance versus broad market indices present challenges for investors seeking stable returns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
